Clearside Biomedical Inc (CLSD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has a cash flow conversion efficiency ratio of 0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($-53.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Clearside Biomedical Inc for the company's overall valuation and market capitalisation.
Clearside Biomedical Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clearside Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearside Biomedical Inc ranked by their cash flow conversion efficiency. Explore Clearside Biomedical Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Star Pacific Tbk
JK:LPLI
|
0.000x |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
-0.245x |
|
Candela Invest SA
BR:CAND
|
0.050x |
|
Braille Energy Systems Inc
V:BES
|
-0.049x |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
|
M&C Saatchi
LSE:SAA
|
0.087x |
|
Miramar Resources Ltd
AU:M2R
|
-0.007x |
|
Edible Garden AG Inc
NASDAQ:EDBL
|
0.028x |
Annual Cash Flow Conversion Efficiency for Clearside Biomedical Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Clearside Biomedical Inc from 2012 to 2024. View CLSD stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-38.85 Million | $-24.70 Million | 0.636x | -44.23% |
| 2023-12-31 | $-15.91 Million | $-18.14 Million | 1.140x | +190.45% |
| 2022-12-31 | $10.61 Million | $-13.37 Million | -1.260x | -345.81% |
| 2021-12-31 | $37.98 Million | $-10.73 Million | -0.283x | +81.12% |
| 2020-12-31 | $8.76 Million | $-13.12 Million | -1.497x | +38.29% |
| 2019-12-31 | $11.16 Million | $-27.07 Million | -2.426x | +27.65% |
| 2018-12-31 | $23.62 Million | $-79.20 Million | -3.353x | -40.57% |
| 2017-12-31 | $21.41 Million | $-51.08 Million | -2.385x | -652.72% |
| 2016-12-31 | $71.66 Million | $-22.71 Million | -0.317x | -183.57% |
| 2015-12-31 | $-36.66 Million | $-13.90 Million | 0.379x | -20.14% |
| 2014-12-31 | $-19.21 Million | $-9.12 Million | 0.475x | -25.44% |
| 2013-12-31 | $-10.74 Million | $-6.84 Million | 0.637x | +104.79% |
| 2012-12-31 | $239.00K | $-3.18 Million | -13.289x | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more